Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt de Vlam

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Brazilian Journal of Physical Therapy|August 31, 2025
Integrating interventions based on cognitive behavioural therapy for insomnia in physical therapist practice for individuals with chronic pain and insomnia: Identifying barriers and formulating implementation strategiesMarine Markaryan, Céline Labie, Sabine Verschueren, et al.
Rheumatology and Therapy|October 28, 2021
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2HLars-Erik Kristensen, Masato Okada, William Tillett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent CohortsDana Quaden, Patrick Vandormael, Pieter Ruytinx, et al.
Advances in Therapy|January 3, 2022
Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO StudyKurt de Vlam, Adrien Nzeusseu Toukap, Marie-Joëlle Kaiser, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
Arthritis Research & Therapy|January 24, 2019
The need for comparative data in spondyloarthritisErnest Choy, Xenofon Baraliakos, Frank Behrens, et al.
Advances in Therapy|April 16, 2022
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled TrialsIrene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, et al.
Arthritis and Rheumatism|April 12, 2011
Systematic candidate gene investigations in the SPA2 locus (9q32) show an association between TNFSF8 and susceptibility to spondylarthritisElena Zinovieva, Amir Kadi, Franck Letourneur, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Brazilian Journal of Physical Therapy|August 31, 2025
Integrating interventions based on cognitive behavioural therapy for insomnia in physical therapist practice for individuals with chronic pain and insomnia: Identifying barriers and formulating implementation strategiesMarine Markaryan, Céline Labie, Sabine Verschueren, et al.
Rheumatology and Therapy|October 28, 2021
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2HLars-Erik Kristensen, Masato Okada, William Tillett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent CohortsDana Quaden, Patrick Vandormael, Pieter Ruytinx, et al.
Advances in Therapy|January 3, 2022
Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO StudyKurt de Vlam, Adrien Nzeusseu Toukap, Marie-Joëlle Kaiser, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
Arthritis Research & Therapy|January 24, 2019
The need for comparative data in spondyloarthritisErnest Choy, Xenofon Baraliakos, Frank Behrens, et al.
Advances in Therapy|April 16, 2022
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled TrialsIrene E van der Horst-Bruinsma, Kurt de Vlam, Jessica A Walsh, et al.
Arthritis and Rheumatism|April 12, 2011
Systematic candidate gene investigations in the SPA2 locus (9q32) show an association between TNFSF8 and susceptibility to spondylarthritisElena Zinovieva, Amir Kadi, Franck Letourneur, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Pageof 14